Thermo Fisher Scientific Symposium

The concept that the immune system plays a critical role in anti-tumour responses has been demonstrated and more recently immune checkpoint therapy has started a revolution in the field of oncology research. Several research studies are ongoing to identify appropriate biomarkers and more recently a multi-biomarker approach is seen as the only path to advance immunotherapies research.

See what thoughts leaders have shared during our symposium about their immuno-oncology and liquid biopsy research.


  • How new biomarkers like TCR sequencing and mutational burden may enhance immunotherapies studies
  • The power of designing your own panels and finding variants with a low limit of detection—down to 0.1% for cell-free DNA samples

Download below what they have presented.

An innovative multi-dimensional NGS approach to understanding the tumour microenvironment and evolution


Jim H. Godsey, PhD
Vice President, R&D,
Clinical Sequencing Division,
Thermo Fisher Scientific

Download now

Current practice, needs and future directions in immuno-oncology research testing


Prof. José Carlos Machado, PhD
Board of Directors member and Group Coordinator,
Porto, Portugal

Download now

Fingerprinting immune responses and improving immunotherapies with TCR sequencing


Dr Noel de Miranda, PhD
Department of Pathology,
Leiden University Medical Center,
Leiden, The Netherlands

Download now

Liquid biopsies sensitive detection in cfDNA in breast and lung cancer


Professor Jacqui Shaw
Leicester Cancer Research Centre,
United Kingdom

Download now